BiotechTube

onabotulinum toxin A

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuropathic Pain

Conditions

Neuropathic Pain

Trial Timeline

Sep 11, 2019 → Jun 30, 2025

NCT ID
NCT03848143

About onabotulinum toxin A

onabotulinum toxin A is a phase 2 stage product being developed by AbbVie for Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT03848143. Target conditions include Neuropathic Pain.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03848143Phase 2Completed

Competing Products

20 competing products in Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
CHF6467 activeComac MedicalPhase 1/2
33
LY3857210 + PlaceboEli LillyPhase 2
52
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
44
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
85
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-1971a + placebo + pregabalinDaiichi SankyoPhase 2
52
DS-5565Daiichi SankyoPhase 3
77
Placebo + MirogabalinDaiichi SankyoPhase 3
77
QutenzaAstellas PharmaPre-clinical
23
Qutenza exposureAstellas PharmaPre-clinical
23
Duloxetine + Pregabalin + PlaceboShionogiApproved
85
LY3016859 + PlaceboEli LillyPhase 2
52
LY3556050 + PlaceboEli LillyPhase 2
52
LY3526318 + PlaceboEli LillyPhase 2
52
LY4065967 + PlaceboEli LillyPhase 2
52
LY3848575 + PlaceboEli LillyPhase 2
52
ABT-639 + pregabalin + PlaceboAbbViePhase 2
52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85